Rineterkib hydrochloride |
Catalog No.GC62448 |
Le chlorhydrate de rineterkib (composé B) est un inhibiteur de ERK1 et ERK2 disponible par voie orale dans le traitement d'une maladie proliférative caractérisée par des mutations activatrices de la voie MAPK. L'activité est particulièrement liée au traitement du NSCLC KRAS-mutant, du NSCLC BRAF-mutant, du cancer du pancréas KRAS-mutant, du cancer colorectal KRAS-mutant (CRC) et du cancer de l'ovaire KRAS-mutant. Le chlorhydrate de Rineterkib peut également inhiber la RAF.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1715025-34-5
Sample solution is provided at 25 µL, 10mM.
Rineterkib hydrochloride (compound B) is an orally active RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer[1].
ERK-IN-1 (compound B) (50, 75 mg/kg, p.o., qd/q2d, 27 days) treatment significantly reduces the tumor volume in the Calu-6 human NSCLC subcutaneous tumor xenograft model in mice[1].
[1]. CAPONIGRO, et al. THERAPEUTIC COMBINATIONS COMPRISING A RAF INHIBITOR AND A ERK INHIBITOR. WO2018051306A1.
Average Rating: 5
(Based on Reviews and 29 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *